INDUSTRIALS · KOSDAQ · 109820

Genematrix

진매트릭스Small-capCommercial Services

What the company does

Genematrix develops diagnostic test kits that detect infectious diseases, including sexually transmitted infections, tuberculosis, human papillomavirus, respiratory infections, and acute gastroenteritis, by analysing genetic material from a patient sample.

Its products are used in clinical and laboratory settings, and it also has vaccine and cancer-immunotherapy programmes in development. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company's core commercial business centres on its NeoPlex product line, which can test for multiple pathogens simultaneously in a single run using proprietary molecular-detection technologies it has developed in-house.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$7.7M
▲ +6.2% YoY
Operating profit · FY2025
−US$492.1K
Loss narrowed
Net income · FY2025
−US$1.3M
Loss narrowed

Revenue

  • FY2023US$7.1M
  • FY2024US$7.3M
  • FY2025US$7.7M

Operating profit

  • FY2023−US$1.8M
  • FY2024−US$1.2M
  • FY2025−US$492.1K

Net income

  • FY2023−US$648.5K
  • FY2024−US$2.7M
  • FY2025−US$1.3M

Key ratios (FY2025)

ROE
-10.5%
Debt/Eq
56.1%
Op. margin
-6.4%
Net margin
-17.2%
Rev. YoY
▲ +6.2%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.